following an abbreviated submission:
beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium 87 micrograms / 5 micrograms / 9 micrograms metered dose inhaler (Trimbow®) is accepted for restricted use within NHS Scotland.
Indication under review: Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
SMC restriction: severe COPD (forced expiratory volume in one second less than 50% predicted normal).
Trimbow costs less than inhalers containing beclometasone dipropionate / formoterol fumarate 100 micrograms/ 6 micrograms and glycopyrronium 44 micrograms administered separately.
Download detailed advice70KB (PDF)
Medicine details
- Medicine name:
- beclometasone dipropionate anhydrous/formoterol fumarate dihydrate/glycopyrronium bromide (Trimbow)
- SMC ID:
- 1274/17
- Indication:
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
- Pharmaceutical company
- Chiesi Limited
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 09 October 2017
In February 2019, the marketing authorisation for beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow®) was extended to include use in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. This change will not be assessed by SMC. The restriction for SMC advice 1274/17 is still valid.